Novo Nordisk liraglutide delayed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's review of Novo Nordisk's diabetes agent liraglutide will probably be delayed "by a couple of months" for an advisory committee review of the GLP-1 analogue, the company reports Sept. 5. The March 2, 2009 meeting is three weeks before liraglutide's user fee date (1"The Pink Sheet" DAILY, Aug. 8, 2008). Liraglutide may be subject to extra scrutiny after recent reports of pancreatitis from Amylin/Lilly's GLP-1 Byetta (exenatide
You may also be interested in...
Victoza beats Byetta
Head-to-head comparison suggests Novo Nordisk's GLP-1 agonist Victoza (liraglutide) is more effective than Amylin/Lilly's Byetta (exenatide) at lowering blood sugar levels. The randomized open-label LEAD-6 study of 464 type 2 diabetes patients who failed to achieve desired targets on standard meds showed Victoza produced a significantly greater drop in HbA1C compared to twice-daily Byetta (1.12 percent versus 0.79 percent). Another study, also presented at the American Diabetes Association meeting June 8, shows those results are long-lasting. But efficacy won't be enough to make liraglutide competitive, and safety issues aren't likely to go away soon. An FDA panel split its vote on approval in light of reports that Victoza raises the risk of thyroid tumors in rodents (1Pharmaceutical Approvals Monthly April 2009, In Brief). Victoza's marketing application remains pending at FDA despite the March 23 user fee date
Novo Nordisk Undeterred By Regulatory Hurdles For Diabetes Drugs
Potential regulatory hurdles for type 2 diabetes drugs -- namely the threat that FDA could require large cardiovascular outcomes studies -- has made the therapeutic area look far less attractive to drug makers than it did a year ago.
Novo Nordisk’s Liraglutide Set For March 2009 PDUFA
Phase II study of once-weekly GLP-1 analog is under way, with results due next year.